Our Process & Overview
Current Investment Opportunities
Healthcare Innovations Alliance
Medical Innovation Summit
Top 10 Medical Innovations
Blog & News
Therapeutics & Diagnostics
Localized Therapy of PSMA Expressing Tumors Utilizing a Radiolabeled PSMA Targeting Tracer
Steve Shih Lin Huang, MD, PhD
Contact Innovation Manager
Jason Ospina, PhD
What is it? What does it do?
Researchers at Cleveland Clinic have developed peptide tracers that target prostate specific membrane antigen (PSMA). These tracers rapidly and specifically accumulate in PSMA+ prostate tumors and metastases of PSMA+ tumor origin. Broad utility of this tracer has been demonstrated as a means for tumor detection and potential applications are envisioned for therapeutic targeting strategies.
Why is it better?
Displays greater specificity and relies on solid phase chemistry for its generation
Approach enables tracer synthesis in less than 24 hours utilizing a peptide synthesizer
Modular in structure and allows coupling to any class of small molecule inhibitors of PSMA
What is its current status?
Specific tracer accumulation in PSMA+ prostate tumor. Mice bearing two human prostate tumor xenographs, one PSMA+ and one PSMA-, were tail vein injected with tracer X-Tc99m and micro SPECT/CT was conducted 4 hours later. Physiological accumulation is noted in the kidneys, bowel and bladder.
Other Technologies by Inventor
Other Technologies by Innovation Manager
VEGF-Ax Anti-angiogenic Diagnostic and Therapeutic Platform
Small Molecule for Hematological Malignancies
Humanized Anti-CD6 mAb for Treating of Autoimmune Diseases
Get in Touch With Us